Evolent Health’s (EVH) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Evolent Health (NYSE:EVH) in a research note published on Tuesday morning,Benzinga reports. They currently have a $20.00 price objective on the technology company’s stock.

Several other research firms have also issued reports on EVH. KeyCorp initiated coverage on shares of Evolent Health in a report on Friday, October 11th. They issued an “overweight” rating and a $35.00 target price for the company. JMP Securities cut their price objective on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Citigroup lowered their price target on shares of Evolent Health from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Stephens lowered shares of Evolent Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $38.00 to $16.00 in a research note on Friday, November 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $30.70.

Evolent Health Stock Down 4.6 %

EVH stock opened at $14.44 on Tuesday. The firm has a fifty day moving average price of $26.17 and a 200 day moving average price of $24.61. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.08. Evolent Health has a fifty-two week low of $13.31 and a fifty-two week high of $35.00.

Insider Buying and Selling at Evolent Health

In related news, COO Emily Ann Rafferty sold 8,861 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total transaction of $265,830.00. Following the completion of the transaction, the chief operating officer now owns 63,408 shares of the company’s stock, valued at $1,902,240. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Evolent Health news, COO Emily Ann Rafferty sold 8,861 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total value of $265,830.00. Following the completion of the transaction, the chief operating officer now directly owns 63,408 shares of the company’s stock, valued at approximately $1,902,240. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Seth Blackley sold 187,904 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the sale, the chief executive officer now directly owns 411,924 shares in the company, valued at $12,357,720. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 307,291 shares of company stock worth $9,290,385. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Headlands Technologies LLC acquired a new position in Evolent Health in the 1st quarter worth about $46,000. Covestor Ltd raised its stake in shares of Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC lifted its position in shares of Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after buying an additional 1,556 shares in the last quarter. Quarry LP acquired a new stake in Evolent Health in the 2nd quarter valued at $32,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Evolent Health in the 2nd quarter worth $61,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.